Search research articles
Contact Us
Filters
Showing results (1-10 of 23) with videos related to
Page
of 3
Sort By:
Expert Review of Anticancer Therapy
|
June 25, 2015
Trametinib in metastatic melanoma
Neha Chopra, Paul D Nathan
The Lancet. Oncology
|
March 21, 2002
The biological treatment of renal-cell carcinoma and melanoma
Paul D Nathan, Tim G Eisen
Expert Review of Anticancer Therapy
|
April 27, 2013
Vemurafenib in melanoma
Heather M Shaw, Paul D Nathan
Future Oncology (London, England)
|
August 23, 2014
Role of the MEK inhibitor trametinib in the treatment of metastatic melanoma
Judy W King, Paul D Nathan
Melanoma Research
|
November 6, 2018
Mycophenolate mofetil alongside high-dose corticosteroids: optimizing the management of combination immune checkpoint inhibitor-induced colitis
Romaana Mir, Heather M Shaw, Paul D Nathan
Cancer Biology & Therapy
|
December 17, 2009
CT response assessment combining reduction in both size and arterial phase density correlates with time to progression in metastatic renal cancer patients treated with targeted therapies
Paul D Nathan, Anup Vinayan, David Stott, et al.
Therapeutic Advances in Medical Oncology
|
March 27, 2023
Tebentafusp: a first-in-class treatment for metastatic uveal melanoma
Sarah Howlett, Thomas J Carter, Heather M Shaw, et al.
NDT Plus
|
May 19, 2015
Anti-CTLA-4 (CD 152) monoclonal antibody-induced autoimmune interstitial nephritis
Elaine C Jolly, Menna R Clatworthy, Christopher Lawrence, et al.
BMC Cancer
|
June 11, 2015
Study design and rationale for a randomised, placebo-controlled, double-blind study to assess the efficacy of selumetinib (AZD6244; ARRY-142886) in combination with dacarbazine in patients with metastatic uveal melanoma (SUMIT)
Richard D Carvajal, Gary K Schwartz, Helen Mann, et al.
The British Journal of Ophthalmology
|
August 31, 2016
Metastatic disease from uveal melanoma: treatment options and future prospects
Richard D Carvajal, Gary K Schwartz, Tongalp Tezel, et al.
Page
of 3
Search research articles
Search
Showing results (1-10 of 23) with videos related to
Sort By:
Page
of 3
Expert Review of Anticancer Therapy
|
June 25, 2015
Trametinib in metastatic melanoma
Neha Chopra, Paul D Nathan
The Lancet. Oncology
|
March 21, 2002
The biological treatment of renal-cell carcinoma and melanoma
Paul D Nathan, Tim G Eisen
Expert Review of Anticancer Therapy
|
April 27, 2013
Vemurafenib in melanoma
Heather M Shaw, Paul D Nathan
Future Oncology (London, England)
|
August 23, 2014
Role of the MEK inhibitor trametinib in the treatment of metastatic melanoma
Judy W King, Paul D Nathan
Melanoma Research
|
November 6, 2018
Mycophenolate mofetil alongside high-dose corticosteroids: optimizing the management of combination immune checkpoint inhibitor-induced colitis
Romaana Mir, Heather M Shaw, Paul D Nathan
Cancer Biology & Therapy
|
December 17, 2009
CT response assessment combining reduction in both size and arterial phase density correlates with time to progression in metastatic renal cancer patients treated with targeted therapies
Paul D Nathan, Anup Vinayan, David Stott, et al.
Therapeutic Advances in Medical Oncology
|
March 27, 2023
Tebentafusp: a first-in-class treatment for metastatic uveal melanoma
Sarah Howlett, Thomas J Carter, Heather M Shaw, et al.
NDT Plus
|
May 19, 2015
Anti-CTLA-4 (CD 152) monoclonal antibody-induced autoimmune interstitial nephritis
Elaine C Jolly, Menna R Clatworthy, Christopher Lawrence, et al.
BMC Cancer
|
June 11, 2015
Study design and rationale for a randomised, placebo-controlled, double-blind study to assess the efficacy of selumetinib (AZD6244; ARRY-142886) in combination with dacarbazine in patients with metastatic uveal melanoma (SUMIT)
Richard D Carvajal, Gary K Schwartz, Helen Mann, et al.
The British Journal of Ophthalmology
|
August 31, 2016
Metastatic disease from uveal melanoma: treatment options and future prospects
Richard D Carvajal, Gary K Schwartz, Tongalp Tezel, et al.
Page
of 3